PMN Insider Trading
Insider Ownership Percentage: 1.50%
Insider Buying (Last 12 Months): $8,655,727.23
Insider Selling (Last 12 Months): $0.00
Promis Neurosciences Share Price & Price History
Current Price: $10.54
Price Change: +0.30 (1.20%)
As of 06/18/2026 04:00 PM ET
Promis Neurosciences Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/22/2026 | Patrick D Kirwin | Director | Buy | 4,000 | $11.33 | $45,320.00 | 4,653 | |
| 3/4/2026 | Eugene Williams | Director | Buy | 2,000 | $24.00 | $48,000.00 | 12,397 | |
| 3/2/2026 | Eugene Williams | Director | Buy | 1,000 | $22.53 | $22,530.00 | 7,397 | |
| 2/19/2026 | Johanne Kaplan | Insider | Buy | 1,629 | $15.35 | $25,005.15 | 3,941 | |
| 2/3/2026 | Abg Management Ltd. | Major Shareholder | Buy | 700,741 | $12.13 | $8,499,988.33 | 943,090 | |
| 10/3/2025 | Max A Milbury | Insider | Buy | 1,215 | $12.25 | $14,883.75 | 1,815 | |
| 2/10/2025 | Neil Cashman | Insider | Buy | 600 | $24.25 | $14,550.00 | 664 | |
| 9/23/2024 | Madge K Shafmaster | Director | Buy | 2,800 | $32.00 | $89,600.00 | 5,533 | |
| 9/20/2024 | Madge K Shafmaster | Director | Buy | 2,400 | $31.25 | $75,000.00 | 2,733 | |
| 8/14/2024 | Patrick D Kirwin | Director | Buy | 400 | $31.25 | $12,500.00 | 2,519 | |
Promis Neurosciences Institutional Trading History
| Reporting Date | Hedge Fund | Shares Held | Market Value | % of Portfolio | Quarterly Change in Shares | Ownership in Company | Details |
|---|
| 6/4/2026 | Seven Fleet Capital Management LP | 10,600 | $0.14M | 0.0% | N/A | 0.118% |  |
| 5/19/2026 | Janus Henderson Group PLC | 1,292,757 | $16.42M | 0.0% | N/A | 14.412% |  |
| 5/19/2026 | Ally Bridge Group NY LLC | 414,219 | $5.26M | 4.2% | +66.1% | 4.618% |  |
| 5/18/2026 | Yu Fan | 329,760 | $4.19M | 4.3% | N/A | 3.676% |  |
| 5/18/2026 | ADAR1 Capital Management LLC | 95,350 | $1.21M | 0.1% | N/A | 1.063% |  |
| 2/18/2026 | Sphera Funds Management LTD. | 11,807 | $81K | 0.0% | -96.0% | 0.549% |  |
| 2/17/2026 | Ally Bridge Group NY LLC | 249,339 | $1.70M | 1.8% | -96.0% | 11.586% |  |
| 11/17/2025 | Armistice Capital LLC | 2,974,518 | $1.26M | 0.0% | +39.1% | 5.528% |  |
| 11/17/2025 | Citadel Advisors LLC | 170,079 | $72K | 0.0% | +168.1% | 0.316% |  |
| 11/17/2025 | Ally Bridge Group NY LLC | 6,233,497 | $2.65M | 1.6% | +367.1% | 11.584% |  |
| 8/14/2025 | Armistice Capital LLC | 2,137,896 | $1.03M | 0.0% | -8.4% | 6.540% |  |
| 5/16/2025 | Allostery Investments LP | 233,703 | $0.17M | 0.2% | +19.8% | 0.715% |  |
| 5/16/2025 | Ally Bridge Group NY LLC | 1,484,699 | $1.03M | 0.9% | -6.8% | 4.542% |  |
| 5/15/2025 | Armistice Capital LLC | 2,334,826 | $1.62M | 0.0% | -7.0% | 7.143% |  |
| 2/17/2025 | Allostery Investments LP | 195,111 | $0.19M | 0.2% | N/A | 0.597% |  |
| 2/14/2025 | Heights Capital Management Inc. | 160,207 | $0.15M | 0.1% | -58.6% | 0.490% |  |
| 11/15/2024 | Sphera Funds Management LTD. | 1,929,297 | $2.41M | 0.4% | +6.3% | 6.455% |  |
| 11/14/2024 | Ally Bridge Group NY LLC | 1,592,605 | $1.99M | 1.1% | +50.3% | 5.328% |  |
| 11/13/2024 | Great Point Partners LLC | 2,790,698 | $3.49M | 1.0% | N/A | 9.337% |  |
| 2/7/2024 | Ieq Capital LLC | 30,799 | $35K | 0.0% | -21.4% | 0.163% |  |
| 11/15/2023 | Affinity Asset Advisors LLC | 265,958 | $0.53M | 0.1% | N/A | 3.100% |  |
| 11/15/2022 | Northeast Financial Consultants Inc | 100,000 | $0.61M | 0.0% | N/A | 1.166% |  |
| 11/4/2022 | Ieq Capital LLC | 39,191 | $0.24M | 0.0% | N/A | 0.457% |  |
Data available starting January 2016
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More on Promis Neurosciences
Today's Range
Now: $10.54
52 Week Range
Now: $10.54
Volume
5,848 shs
Average Volume
19,483 shs
Market Capitalization
$94.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A
Who are the company insiders with the largest holdings of Promis Neurosciences?
Who are the major institutional investors of Promis Neurosciences?
Which major investors are buying Promis Neurosciences stock?
During the last quarter, PMN stock was purchased by institutional investors including:
- Janus Henderson Group PLC
- Yu Fan
- Ally Bridge Group NY LLC
- ADAR1 Capital Management LLC
- Seven Fleet Capital Management LP
In the last year, these company insiders have bought Promis Neurosciences stock:
- Abg Management Ltd (Major Shareholder)
- Eugene Williams (Director)
- Madge K Shafmaster (Director)
- Patrick D Kirwin (Director)
- Johanne Kaplan (Insider)
- Max A Milbury (Insider)
- Neil Cashman (Insider)
Learn More investors buying Promis Neurosciences stock.